Acorai is a Swedish medical device startup based in Helsingborg, founded in 2019. The company focuses on developing innovative solutions for non-invasive intracardiac pressure monitoring (ICPM) to enhance heart failure management. With over 64 million people affected by heart failure worldwide, Acorai aims to provide accessible and accurate hemodynamic monitoring without the risks associated with invasive procedures. The company has gained recognition in the healthcare technology sector, receiving FDA designation as a Breakthrough Device in 2023. Acorai's primary offering is the Acorai Heart Monitor, a portable device that utilizes the proprietary SAVE Sensor System. This system combines various sensor technologies and machine learning algorithms to provide real-time insights into critical hemodynamic parameters, such as right atrial pressure and pulmonary artery pressure. The device is designed for ease of use in clinical settings, allowing healthcare professionals to make timely decisions based on accurate data. Acorai's technology aims to reduce hospitalizations, enhance patient safety, and improve overall healthcare efficiency, with a target market entry in the U.S. planned for the second half of 2025.